Home › Compare › MYNDF vs PFE

MYNDF vs PFE: Dividend Comparison 2026

MYNDF yields 24691.36% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYNDF wins by $425698500507688960000.00M in total portfolio value
10 years
MYNDF
MYNDF
● Live price
24691.36%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$425698500507688960000.00M
Annual income
$422,333,782,887,035,300,000,000,000.00
Full MYNDF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MYNDF vs PFE

📍 MYNDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYNDFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYNDF + PFE cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MYNDF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYNDF
Annual income on $10K today (after 15% tax)
$2,098,765.43/yr
After 10yr DRIP, annual income (after tax)
$358,983,715,453,980,050,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MYNDF beats the other by $358,983,715,453,980,050,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYNDF + PFE for your $10,000?

MYNDF: 50%PFE: 50%
100% PFE50/50100% MYNDF
Portfolio after 10yr
$212849250253844480000.00M
Annual income
$211,166,891,443,517,660,000,000,000.00/yr
Blended yield
99.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MYNDF
No analyst data
Altman Z
-36.4
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYNDF buys
0
PFE buys
0
No recent congressional trades found for MYNDF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYNDFPFE
Forward yield24691.36% ✓6.13%
Annual dividend / share$2.00 ✓$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2% ✓
Portfolio after 10y$425698500507688960000.00M ✓$49.6K
Annual income after 10y$422,333,782,887,035,300,000,000,000.00 ✓$26,258.71
Total dividends collected$425476848484806557696.00M ✓$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MYNDF vs PFE ($10,000, DRIP)

YearMYNDF PortfolioMYNDF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,479,836$2,469,135.80$9,153$693.39+$2.47M → MYNDF
2$574,901,215$572,247,791.04$8,593$849.25+$574.89M → MYNDF
3$124,600,573,045$123,985,428,744.76$8,336$1,066.78+$124600.56M → MYNDF
4$25,247,195,017,151$25,113,872,403,992.51$8,437$1,384.80+$25247195.01M → MYNDF
5$4,782,808,127,363,296$4,755,793,628,694,945.00$9,013$1,875.40+$4782808127.35M → MYNDF
6$847,111,701,963,487,400$841,994,097,267,208,600.00$10,306$2,680.72+$847111701963.48M → MYNDF
7$140,280,803,424,148,060,000$139,374,393,903,047,110,000.00$12,820$4,101.38+$140280803424148.05M → MYNDF
8$21,720,429,872,935,753,000,000$21,570,329,413,271,914,000,000.00$17,673$6,826.70+$21720429872935752.00M → MYNDF
9$3,144,595,907,152,942,000,000,000$3,121,355,047,188,900,000,000,000.00$27,543$12,591.86+$3144595907152941568.00M → MYNDF
10$425,698,500,507,688,960,000,000,000$422,333,782,887,035,300,000,000,000.00$49,560$26,258.71+$425698500507688960000.00M → MYNDF

MYNDF vs PFE: Complete Analysis 2026

MYNDF — Stock

MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company is headquartered in Kelowna, Canada.

Full MYNDF Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MYNDF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYNDF vs SCHDMYNDF vs JEPIMYNDF vs OMYNDF vs KOMYNDF vs MAINMYNDF vs JNJMYNDF vs MRKMYNDF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.